The price of Anavex Life Sciences Corporation (NASDAQ: AVXL) closed at $4.23 in the last session, down -1.51% from day before closing price of $4.30. On the day, 1085823 shares were traded.
Ratios:
We take a closer look at AVXL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 11.85 and its Current Ratio is at 11.85. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Cantor Fitzgerald on December 06, 2022, Downgraded its rating to Neutral and sets its target price to $11 from $16 previously.
On June 23, 2022, Berenberg started tracking the stock assigning a Buy rating and target price of $40.
On September 23, 2021, BTIG Research started tracking the stock assigning a Buy rating and target price of $35.BTIG Research initiated its Buy rating on September 23, 2021, with a $35 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 28 ’24 when MISSLING CHRISTOPHER U sold 73,380 shares for $5.11 per share. The transaction valued at 374,972 led to the insider holds 1,250,210 shares of the business.
MISSLING CHRISTOPHER U sold 268,000 shares of AVXL for $2,139,310 on Jun 28 ’23. The President and CEO now owns 1,018,210 shares after completing the transaction at $7.98 per share.
Stock Price History:
Over the past 52 weeks, AVXL has reached a high of $10.45, while it has fallen to a 52-week low of $4.16.
Shares Statistics:
A total of 82.07M shares are outstanding, with a floating share count of 79.52M. Insiders hold about 3.16% of the company’s shares, while institutions hold 31.68% stake in the company.
Earnings Estimates
The company has Anavex Life Sciences Corp. analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $17.00, with high estimates of $6.99 and low estimates of $456.31.
Analysts are recommending an EPS of between $Consumer Cyclical and $Financial Services for the fiscal current year, implying an average EPS of $Healthcare.
